-
公开(公告)号：US11865100B2
公开(公告)日：2024-01-09
申请号：US17154689
申请日：2021-01-21
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer Toledano , Ofra Levy-Hacham , Ori Nov , Vered Ram
CPC classification number: A61K31/327 , A61K9/0014 , A61K9/06 , A61K9/10 , A61K9/107 , A61K9/50 , A61P17/00 , A61P17/10
Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
-
公开(公告)号：US10420743B2
公开(公告)日：2019-09-24
申请号：US16033257
申请日：2018-07-12
Applicant: SOL-GEL TECHNOLOGIES LTD.
Inventor： Ofer Toledano , Ori Nov
IPC: A61K9/50 , A61K31/203 , A61K31/327 , A61P17/10 , A61K9/00
Abstract: The present application is directed to regimens, methods of treatment, and compositions for the treatment of acne in a subject suffering therefrom.
-
公开(公告)号：US11628155B2
公开(公告)日：2023-04-18
申请号：US16794692
申请日：2020-02-19
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer Toledano , Ori Nov
Abstract: A regimen and a pharmaceutical composition for the treatment of rosacea are described. The regimen includes topically applying to the skin of a subject in need of such treatment a pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and the pharmaceutically acceptable carrier or excipient, where the benzoyl peroxide is the only active ingredient in the pharmaceutical composition, and the pharmaceutical composition is a cream or an emulsion.
-
公开(公告)号：US20200316005A1
公开(公告)日：2020-10-08
申请号：US16897308
申请日：2020-06-10
Applicant: SOL-GEL TECHNOLOGIES LTD.
Inventor： Ofer Toledano , Ori Nov
IPC: A61K31/203 , A61K9/00 , A61P17/10 , A61K9/50 , A61K31/327
Abstract: The present application is directed to regimens, methods of treatment, and compositions for the treatment of acne in a subject suffering therefrom.
-
公开(公告)号：US11877997B2
公开(公告)日：2024-01-23
申请号：US17156941
申请日：2021-01-25
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer Toledano , Ofra Levy-Hacham , Ori Nov , Vered Ram
CPC classification number: A61K31/327 , A61K9/0014 , A61K9/06 , A61K9/10 , A61K9/107 , A61K9/50 , A61P17/00 , A61P17/10
Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.
-
Patent Agency Ranking
公开(公告)号：US20210315834A1
公开(公告)日：2021-10-14
申请号：US17227459
申请日：2021-04-12
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ori Nov , Marcel Zighelboim , Karine Neimann
IPC: A61K31/05 , A61K45/06 , A61K9/00 , A61K31/517 , A61K31/4174 , A61K9/06
Abstract: The present invention is directed to a composition comprising aryl hydrocarbon receptor (AhR) agonists and combinations for the prevention and treatment of alopecia and hair loss, e.g. when such conditions are caused by chemotherapy, radiation therapy or hormone replacement therapy.
-
公开(公告)号：US10945987B2
公开(公告)日：2021-03-16
申请号：US16794734
申请日：2020-02-19
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer Toledano , Ofra Levy-Hacham , Ori Nov , Vered Ram
Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.
-
公开(公告)号：US12295935B2
公开(公告)日：2025-05-13
申请号：US18123702
申请日：2023-03-20
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer Toledano , Ori Nov
Abstract: A regimen and a pharmaceutical composition for the treatment of a skin condition and/or skin affliction are described. The regimen includes topically applying to the skin of a subject in need of such treatment a pharmaceutical composition comprising about 2.5% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient.
-
公开(公告)号：US11633399B2
公开(公告)日：2023-04-25
申请号：US16737503
申请日：2020-01-08
Applicant: SOL-GEL TECHNOLOGIES LTD.
Inventor： Moshe Arkin , Marcel Zighelboim , Ori Nov , Ofer Toledano , Karine Neimann
IPC: A61K31/505 , A61K31/517 , A61K31/5377 , A61K39/395 , A61K9/00 , A61K45/06 , A61K31/05 , A61K9/06 , A61K31/506
Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.
-
公开(公告)号：US11426378B2
公开(公告)日：2022-08-30
申请号：US16794887
申请日：2020-02-19
Applicant: Sol-Gel Technologies Ltd.
Inventor： Ofer Toledano , Ofra Levy-Hacham , Ori Nov , Vered Ram
Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in the pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75%.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.015 seconds)
